Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance

[1]  W. Wick,et al.  Understanding and targeting alkylator resistance in glioblastoma. , 2014, Cancer discovery.

[2]  Michael Kahn,et al.  Can we safely target the WNT pathway? , 2014, Nature Reviews Drug Discovery.

[3]  David M. Wilson,et al.  DNA repair mechanisms in dividing and non-dividing cells. , 2013, DNA repair.

[4]  S. Krauss,et al.  A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. , 2013, Cancer research.

[5]  F. Rassool,et al.  DNA double-strand break response in stem cells: mechanisms to maintain genomic integrity. , 2013, Biochimica et biophysica acta.

[6]  R. Moon,et al.  WNT signalling pathways as therapeutic targets in cancer , 2012, Nature Reviews Cancer.

[7]  Scott L. Pomeroy,et al.  Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.

[8]  Kerstin Pingel,et al.  50 Years of Image Analysis , 2012 .

[9]  M. Kool,et al.  Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours , 2012, British Journal of Cancer.

[10]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[11]  H. Dinh,et al.  A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. , 2012, Cancer research.

[12]  M. Christmann,et al.  O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry. , 2011, Biochimica et biophysica acta.

[13]  T. Kipps,et al.  Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells , 2011, Proceedings of the National Academy of Sciences.

[14]  Hendrik Witt,et al.  Medulloblastoma comprises four distinct molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Margison,et al.  Targeting O6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy , 2010, Cellular and Molecular Life Sciences.

[16]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[17]  Marc W. Kirschner,et al.  Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling , 2009, Nature.

[18]  Sharmistha Sarkar,et al.  A Two-Step Model for Colon Adenoma Initiation and Progression Caused by APC Loss , 2009, Cell.

[19]  Allan H Friedman,et al.  Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Eksborg,et al.  Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets. , 2008, Neuro-oncology.

[21]  Dirk Troost,et al.  Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features , 2008, PloS one.

[22]  Elin Lindhagen,et al.  The fluorometric microculture cytotoxicity assay , 2008, Nature Protocols.

[23]  Nihal Ahmad,et al.  Dose translation from animal to human studies revisited , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  Hans Clevers,et al.  Mining the Wnt pathway for cancer therapeutics , 2007, Nature Reviews Drug Discovery.

[25]  S. Eksborg,et al.  Celecoxib Prevents Neuroblastoma Tumor Development and Potentiates the Effect of Chemotherapeutic Drugs In vitro and In vivo , 2007, Clinical Cancer Research.

[26]  K. Druey,et al.  Prostaglandin E2 Promotes Colon Cancer Cell Growth Through a Gs-Axin-ß-Catenin Signaling Axis , 2005, Science.

[27]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[28]  R. Stupp,et al.  Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients , 2004, Clinical Cancer Research.

[29]  F. Holstege,et al.  Specific inhibition of gene expression using a stably integrated, inducible small‐interfering‐RNA vector , 2003, EMBO reports.

[30]  Ajamete Kaykas,et al.  Zebrafish Prickle, a Modulator of Noncanonical Wnt/Fz Signaling, Regulates Gastrulation Movements , 2003, Current Biology.

[31]  B. Levin,et al.  A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis , 2002, Gut.

[32]  Xavier Messeguer,et al.  PROMO: detection of known transcription regulatory elements using species-tailored searches , 2002, Bioinform..

[33]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[34]  P. Houghton,et al.  Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  C. Ramana,et al.  Activation of human O6-methylguanine-DNA methyltransferase gene by glucocorticoid hormone , 1999, Oncogene.

[36]  M. Prados,et al.  Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. , 1996, Cancer research.

[37]  S. Piantadosi,et al.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. , 1993, The New England journal of medicine.